Gonal-F

Gonal-F is a prescription medication that contains the recombinant follicle-stimulating hormone follitropin alfa. It is supplied as a sterile solution for subcutaneous injection; the specific strength is not listed in the provided data. Gonal-F belongs to the class of recombinant follicle-stimulating hormones and is used in fertility treatment protocols. The product is marketed in the European Union and requires a health-care professional’s prescription in the EU market.

Gonal-F is indicated for several fertility-related conditions where stimulation of follicular development is required.

- Infertility due to anovulation, such as in polycystic ovary syndrome. - Controlled ovarian stimulation for assisted reproductive technology procedures, including in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI). - Treatment of hypogonadotropic hypogonadism in women who have insufficient endogenous follicle-stimulating hormone production. - Ovulation induction in women undergoing intra-uterine insemination (IUI) protocols. - Adjunct therapy in donor-egg cycles to support the recipient’s endometrial preparation.

The safety profile of Gonal-F reflects its hormonal activity; side effects are reported across a range of frequencies.

Common: - Local injection-site reactions such as redness, swelling, itching, or mild pain that usually resolve within a few days. - Headache, mild dizziness, or transient visual disturbances. - Abdominal discomfort, bloating, or mild pelvic pressure. - Mood changes including irritability, emotional lability, or mild anxiety.

Serious: - Ovarian hyperstimulation syndrome (OHSS), a condition that can cause rapid weight gain, severe abdominal pain, nausea, vomiting, and shortness of breath, potentially requiring hospitalization. - Multiple pregnancy (twins, triplets, or higher order) resulting from excessive follicular response, which increases obstetric risk. - Ovarian cyst formation or significant ovarian enlargement that may need imaging and specialist follow-up.

Before initiating Gonal-F therapy, clinicians should evaluate patient history and monitor specific clinical parameters to minimise risk.

- Confirm diagnosis of anovulation or hypogonadotropic hypogonadism and assess baseline ovarian reserve. - Perform ultrasound monitoring of follicular development to adjust dosing and prevent ovarian hyperstimulation. - Avoid use in patients with active ovarian, breast, or uterine malignancies, or uncontrolled thyroid disease. - Counsel women of reproductive age about the potential for multiple gestations and the need for contraception after treatment if pregnancy is not desired. - Review any history of allergic reactions to recombinant proteins or excipients in the formulation. - Consider dose adjustments in patients with renal or hepatic impairment, although data are limited.

Gonal-F may interact with other medications or substances that affect ovarian response or hormone metabolism; awareness of these interactions helps optimise treatment outcomes.

Avoid: - Concurrent use of gonadotropin-releasing hormone (GnRH) antagonists that suppress endogenous FSH activity, which can diminish the intended ovarian stimulation. - Hormonal contraceptives or estrogen-containing products during the stimulation phase, as they may interfere with follicular development.

Use with caution: - Medications that increase the risk of thrombosis, such as oral anticoagulants or selective estrogen receptor modulators, because of the estrogen rise associated with follicular growth. - Thyroid hormone replacement therapy; dose adjustments may be needed due to altered hormone dynamics during stimulation. - Antipsychotic or antidepressant drugs that affect prolactin levels, potentially influencing ovarian response.